Press Releases

Encouraging interim data from a phase 1 clinical study evaluating MOv18 IgE in cancer patients with advanced solid tumours presented at the AACR Virtual Annual Meeting

MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Results support, for the first time, the safety and potential efficacy of an IgE antibody as...

Read more

Interim phase 1 data evaluating MOv18 IgE, an anti-folate receptor alpha IgE antibody, in cancer patients with advanced solid tumours to be presented at the AACR Virtual Annual Meeting

MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials Folate receptor alpha most commonly overexpressed on tumour cells in ovarian cancer London...

Read more

Epsilogen licences MOv18 IgE, an anti-folate receptor alpha IgE antibody from King’s College London

MOv18 IgE is currently in phase 1 clinical trial in cancer patients with advanced solid tumours Folate receptor alpha most commonly overexpressed on tumour cells in...

Read more

IGEM Therapeutics appoints Dr David Chiswell as a Non-Executive Chairman

Cambridge Antibody Technology co-founder and CEO, Dr Chiswell brings 30 years of biotechnology experience to IGEM Therapeutics’s Board London, 9 April 2019 – IGEM...

Read more

IGEM Therapeutics announces further UK government funding to develop novel IgE antibody targeting solid tumours expressing HER2

Company receives grant from Innovate UK Biomedical Catalyst Primer Award London, 2 April 2019 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel...

Read more

IGEM Therapeutics announces final close of £5 million Series A financing round

New investors Alsa Holdings and UCL Technology Fund join Epidarex Capital Proceeds will allow IGEM Therapeutics to continue development of IgE therapeutic antibody...

Read more

IGEM Therapeutics awarded “Best Start-up Biotech Company” at the 2018 OBN Awards

London, 12 October 2018 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced...

Read more

IGEM Therapeutics shortlisted as a finalist in the “Best Start-up Biotech Company”

IGEM Therapeutics shortlisted as a finalist in the “Best Start-up Biotech Company” category of the 2018 OBN Awards  London, 22 August 2018– IGEM Therapeutics (IGEM)...

Read more

IGEM Therapeutics announces UK government funding to develop a novel IgE antibody targeting solid tumours

£1.45 million grant from Innovate UK Biomedical Catalyst Funds enable IGEM Therapeutics to progress second product candidate towards the clinic London, 9 May 2018 –...

Read more

IONTAS and Epsilogen collaborate to identify novel IgE antibodies for cancer targets

Cambridge, UK, 04 April 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced today that it will collaborate...

Read more